OBJECTIVE: We investigated the impact of the first year of highly active antiretroviral therapy (HAART) on health-related quality of life (HRQL). METHODS: Medical data for patients in the French APROCO cohort were collected at enrollment (M0) and month 12 (M12). A self-administered questionnaire gathered information about HRQL (Medical Outcome Study 36-Item Short Form Health Survey) and toxicity-related symptoms. Using the twenty-fifth percentile of HRQL scales in the French population as a threshold, patients with normal values in at least three mental and three physical scales were considered to have a "normal HRQL." RESULTS. Of the 1053 patients followed through M12, HRQL data at M0 and M12 were available for 654. Among the 233 patients with a normal baseline HRQL, 63 (27.0%) experienced a deterioration of HRQL at M12. Among the 421 patients with a low baseline HRQL, 121 achieved a normal HRQL at M12. Logistic regression showed that factors independently associated with a normal HRQL at M12 were normal baseline HRQL, baseline CD4 count <500 cells/mm, time since HIV diagnosis <8 years, undetectable HIV-RNA at M12, and lower number of self-reported symptoms at M12. CONCLUSION: An assessment of HRQL should be integrated to efficacy outcomes to evaluate and compare long-term strategies properly and to optimize the durability of response to antiretroviral therapy.
OBJECTIVE: We investigated the impact of the first year of highly active antiretroviral therapy (HAART) on health-related quality of life (HRQL). METHODS: Medical data for patients in the French APROCO cohort were collected at enrollment (M0) and month 12 (M12). A self-administered questionnaire gathered information about HRQL (Medical Outcome Study 36-Item Short Form Health Survey) and toxicity-related symptoms. Using the twenty-fifth percentile of HRQL scales in the French population as a threshold, patients with normal values in at least three mental and three physical scales were considered to have a "normal HRQL." RESULTS. Of the 1053 patients followed through M12, HRQL data at M0 and M12 were available for 654. Among the 233 patients with a normal baseline HRQL, 63 (27.0%) experienced a deterioration of HRQL at M12. Among the 421 patients with a low baseline HRQL, 121 achieved a normal HRQL at M12. Logistic regression showed that factors independently associated with a normal HRQL at M12 were normal baseline HRQL, baseline CD4 count <500 cells/mm, time since HIV diagnosis <8 years, undetectable HIV-RNA at M12, and lower number of self-reported symptoms at M12. CONCLUSION: An assessment of HRQL should be integrated to efficacy outcomes to evaluate and compare long-term strategies properly and to optimize the durability of response to antiretroviral therapy.
Authors: I Ruiz Perez; J Rodriguez Baño; M A Lopez Ruz; A del Arco Jimenez; M Causse Prados; J Pasquau Liaño; P Martin Rico; J de la Torre Lima; J L Prada Pardal; M Lopez Gomez; N Muñoz; D Morales; M Marcos Journal: Qual Life Res Date: 2005-06 Impact factor: 4.147
Authors: Steven A Safren; Ellen S Hendriksen; Laura Smeaton; David D Celentano; Mina C Hosseinipour; Ronald Barnett; Juan Guanira; Timothy Flanigan; N Kumarasamy; Karin Klingman; Thomas Campbell Journal: AIDS Behav Date: 2012-02
Authors: Darren J Clayson; Diane J Wild; Paul Quarterman; Isabelle Duprat-Lomon; Maria Kubin; Stephen Joel Coons Journal: Pharmacoeconomics Date: 2006 Impact factor: 4.981
Authors: Andrew Tomita; Nigel Garrett; Lise Werner; Jonathan K Burns; Nelisiwe Ngcobo; Nomthandazo Zuma; Koleka Mlisana; Francois van Loggerenberg; Salim S Abdool Karim Journal: AIDS Behav Date: 2014-09
Authors: Robert Burgoyne; Evan Collins; Cheryl Wagner; Susan Abbey; Mark Halman; Margaret Nur; Sharon Walmsley Journal: Qual Life Res Date: 2005-05 Impact factor: 4.147
Authors: Honghong Wang; Jun Zhou; Gouping He; Yang Luo; Xianhong Li; Aiyun Yang; Kristopher Fennie; Ann B Williams Journal: AIDS Res Hum Retroviruses Date: 2009-08 Impact factor: 2.205